4.3 Review

Community-associated methicillin-resistant Staphylococcus aureus skin infections: advances toward identifying the key virulence factors

Journal

CURRENT OPINION IN INFECTIOUS DISEASES
Volume 21, Issue 2, Pages 147-152

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0b013e3282f64819

Keywords

CA-MRSA; skin infection; virulence

Funding

  1. Intramural NIH HHS Funding Source: Medline
  2. NCRR NIH HHS [P20RR020185, P20RR16455-07] Funding Source: Medline
  3. NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020185, P20RR016455] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI001079] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Purpose of review In recent years there has been an increase in the incidence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections in healthy individuals, the cause of which is largely unknown. CA-MRSA primarily causes skin and soft-tissue infections but certain strains are also associated with unusually severe pathology. The purpose of this review is to provide a critical analysis of our current knowledge of virulence factors contributing to skin and soft-tissue infections caused by CA-MRSA. Recent findings Isolates classified as pulsed-field gel electrophoresis type USA300 have emerged as the predominant CA-MRSA genotype and in most geographic areas account for 97% or more of CA-MRSA infections. Recent key studies, such as those reporting the complete genome sequence of USA300, and the discovery of cytolytic peptides that contribute significantly to CA-MRSA virulence, lead the way for future investigations. Summary Although we have only a cursory understanding of the molecular mechanisms of CA-MRSA virulence, studies using clinically relevant CA-MRSA isolates are beginning to identify virulence determinants specific to this pathogen. Identifying CA-MRSA virulence determinants and the concerted regulation of these factors will foster development of vaccines and therapeutics designed to control CA-MRSA skin infections.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available